| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Puromycin-sensitive aminopeptidase, PSA, Cytosol alanyl aminopeptidase, AAP-S, NPEPPS, PSA |
| Entrez GeneID | 9520 |
| WB Predicted band size | 103.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This PSA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 536-565 amino acids from the Central region of human PSA. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是3篇关于PSA抗体的经典文献示例(内容基于公开研究概括，非真实文献)：
---
1. **文献名称**: *Cross-reactivity of anti-PSA antibodies with human glandular kallikreins*
**作者**: Christensson A, et al. (1993)
**摘要**: 研究揭示了不同单克隆PSA抗体与人类其他激肽释放酶家族蛋白(如hK2)的交叉反应性，对提高PSA检测特异性具有重要意义。
2. **文献名称**: *Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate*
**作者**: Balk SP, et al. (2003)
**摘要**: 系统综述了PSA抗体的临床应用，阐明其在前列腺癌筛查中的敏感性和局限性，并探讨了抗体表位选择对检测结果的影响。
3. **文献名称**: *Comparison of free and total PSA assays using novel antibody pair combinations*
**作者**: Sokoll LJ, et al. (2010)
**摘要**: 通过优化游离PSA和结合型PSA抗体的配对组合，开发了高精度检测方法，显著改善了前列腺癌与良性增生的鉴别诊断。
---
注：以上为示例性内容，实际文献需通过PubMed/Google Scholar等平台检索关键词(如"PSA antibody specificity"或"PSA immunoassay")获取。
Prostate-specific antigen (PSA), also known as kallikrein-3 (KLK3), is a glycoprotein enzyme produced primarily by prostate epithelial cells. Discovered in the 1970s, PSA gained clinical prominence as a biomarker for prostate cancer screening, diagnosis, and monitoring. It functions in semen liquefaction by cleaving seminal proteins. While elevated serum PSA levels are strongly associated with prostate cancer, they may also occur in benign conditions like prostatic hyperplasia or inflammation, necessitating careful interpretation.
PSA antibodies are immunodetection tools critical for quantifying PSA in diagnostic assays. Monoclonal antibodies targeting specific PSA epitopes were developed in the 1980s-1990s, forming the basis for modern immunoassays (e.g., ELISA, chemiluminescent assays). These antibodies distinguish free PSA (unbound) from complexed PSA (bound to serum proteins), aiding in differentiating malignant from benign prostate conditions. Recent advancements include ultra-sensitive PSA assays for post-treatment surveillance and nanoparticle-conjugated antibodies for imaging. However, challenges persist in specificity, as PSA antibodies may cross-react with homologous kallikreins. Research continues to refine antibody specificity and develop therapeutic applications, such as antibody-drug conjugates targeting PSA-expressing tumors. Despite emerging biomarkers, PSA remains central in prostate cancer management, with antibody-based detection underpinning its clinical utility.
×
